Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Assessment of Structural Basis for Thiazolopyridine Derivatives as DNA Gyrase-B Inhibitors

Author(s): Vishal Prakash Zambre*, Nilesh Narayan Petkar, Vishal Pravin Dewoolkar, Swapnali Vilas Bhadke and Sanjay Dinkar Sawant

Volume 20, Issue 4, 2023

Published on: 27 March, 2023

Article ID: e220223213933 Pages: 23

DOI: 10.2174/1570163820666230222151558

Price: $65

Abstract

Background: Tuberculosis (TB) is one of the leading causes of death in the post-COVID- 19 era. It has been observed that there is a devastating condition with a 25-30% increase in TB patients. DNA gyrase B isoform has proved its high potential to be a therapeutically effective target for developing newer and safer anti-TB agents.

Objective: This study aims to identify minimum structural requirements for the optimization of thiazolopyridine derivatives having DNA gyrase inhibitory activities. Moreover, developed QSAR models could be used to design new thiazolopyridine derivatives and predict their DNA gyrase B inhibitory activity before synthesis.

Methods: 3D-QSAR and Group-based QSAR (G-QSAR) methodologies were adopted to develop accurate, reliable, and predictive QSAR models. Statistical methods such as kNN-MFA SW-FB and MLR SW-FB were used to correlate dependent parameters with descriptors. Both models were thoroughly validated for internal and external predictive abilities.

Results: The 3D-QSAR model significantly correlated steric and electrostatic descriptors with q2 0.7491 and predicted r2 0.7792. The G-QSAR model showed that parameters such as SsOHE-index, slogP, ChiV5chain, and T_C_C_3 were crucial for optimizing thiazolopyridine derivatives as DNA gyrase inhibitors. The 3D-QSAR model was interpreted extensively with respect to 3D field points, and the pattern of fragmentation was studied in the G-QSAR model.

Conclusion: The 3D-QSAR and G-QSAR models were found to be highly predictive. These models could be useful for designing potent DNA gyrase B inhibitors before their synthesis.

Graphical Abstract

[1]
World Health OrganizationGlobal tuberculosis report 2020. Available from: https://www.who.int/publications/i/item/9789240013131 (Accessed on: April 7, 2022).
[2]
Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51(1): 6-14.
[http://dx.doi.org/10.1086/653115] [PMID: 20504231]
[3]
Udwadia Z. Totally drug resistant-tuberculosis in India: The bad just got worse. J Assoc Chest Phys 2016; 4(2): 41.
[http://dx.doi.org/10.4103/2320-8775.183836]
[4]
Organization WH. World Health Organization multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland. In. 2010; 1-71.
[5]
Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12(5): 388-404.
[http://dx.doi.org/10.1038/nrd4001] [PMID: 23629506]
[6]
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020; 382(10): 893-902.
[http://dx.doi.org/10.1056/NEJMoa1901814] [PMID: 32130813]
[7]
Zidar N, Macut H, Tomašič T, et al. New N -phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors. MedChemComm 2019; 10(6): 1007-17.
[http://dx.doi.org/10.1039/C9MD00224C] [PMID: 31303999]
[8]
Chopra S, Matsuyama K, Tran T, et al. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67(2): 415-21.
[http://dx.doi.org/10.1093/jac/dkr449] [PMID: 22052686]
[9]
Kale RR, Kale MG, Waterson D, et al. Thiazolopyridone ureas as DNA gyrase B inhibitors: Optimization of antitubercular activity and efficacy. Bioorg Med Chem Lett 2014; 24(3): 870-9.
[http://dx.doi.org/10.1016/j.bmcl.2013.12.080] [PMID: 24405701]
[10]
Zambre VP, Hambarde VA, Petkar NN, Patel CN, Sawant SD. Structural investigations by in silico modeling for designing NR2B subunit selective NMDA receptor antagonists. RSC Advances 2015; 5(30): 23922-40.
[http://dx.doi.org/10.1039/C5RA01098E]
[11]
Zambre VP, Patil RB, Sangshetti JN, Sawant SD. Comprehensive QSAR studies reveal structural insights into the NR2B subtype selective benzazepine derivatives as N-Methyl-Aspartate receptor antagonists. J Mol Struct 2019; 1197: 617-27.
[http://dx.doi.org/10.1016/j.molstruc.2019.07.068]
[12]
Kale MG, Raichurkar A, P SH, et al. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. J Med Chem 2013; 56(21): 8834-48.
[http://dx.doi.org/10.1021/jm401268f] [PMID: 24088190]
[13]
Ghorpade SR, Kale MG, McKinney DC, Hameed S, Raichurkar AK. Thaizolo [5,4-B] Pyridine and oxazolo [5,4-B] Pyridine derivatives as antibacterial agents. WO2009147431A1, December 10 2009.
[14]
VLifeMDS: Molecular Design Suite, VLife Sciences Technologies Pvt. Ltd., Pune, India. 2010. Available from : www.vlifesciences.com
[15]
Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980; 36(22): 3219-28.
[http://dx.doi.org/10.1016/0040-4020(80)80168-2]
[16]
Shen M, LeTiran A, Xiao Y, Golbraikh A, Kohn H, Tropsha A. Quantitative structure-activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods. J Med Chem 2002; 45(13): 2811-23.
[http://dx.doi.org/10.1021/jm010488u] [PMID: 12061883]
[17]
Ajmani S, Jadhav K, Kulkarni SA. Group-based QSAR (G-QSAR): Mitigating interpretation challenges in QSAR. QSAR Comb Sci 2009; 28(1): 36-51.
[http://dx.doi.org/10.1002/qsar.200810063]
[18]
Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002; 20(4): 269-76.
[http://dx.doi.org/10.1016/S1093-3263(01)00123-1] [PMID: 11858635]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy